Artificial transaminase for synthesizing sitagliptin
By designing and mutating aminotransferases AT0 and AT16, the problem of high cost and complex post-treatment of DMSO in the prior art is solved, and the synthesis of sitagliptin efficiently is achieved in methanol solution, reducing production costs and maintaining high stereoscopicity Selective.
Patent Information
- Application Number
- CN202411276485.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-12-06
AI Technical Summary
When using DMSO as an organic cosolvent, the production cost is high and the post-processing is complex. Artrobacter sp. transaminase and its mutants are patented, making it difficult to develop a reaction system for methanol-solubilization of new aminotransferases.
Based on the existing amino acid sequence and structural model of (R)-ω-transaminase, the artificially synthesized transaminase AT0 was designed and verified through computer simulation, and further mutation to AT16, with high enzyme activity and stereoselectivity in methanol solution. , suitable for catalyzing the synthesis of sitagliptin.
The efficient catalytic synthesis of sitagliptin in methanol solution is achieved, reducing production costs, and maintaining high stereoselectivity and enzyme activity, avoiding the inhibitory properties of substrates and products.
Smart Images

Figure BDA0005040339590000011 
Figure BDA0005040339590000061 
Figure BDA0005040339590000101
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biosynthesis, and in particular relates to an artificial transaminase and an application thereof in the preparation of sitagliptin. Background Art
[0002] Incretin hormones include glucagon-like polypeptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which participate in the physiological regulation of glucose homeostasis in the human body. When blood glucose concentration is normal or elevated, GLP-1 and GIP can increase the synthesis and release of insulin by pancreatic β cells through intracellular signaling pathways involving cyclic adenosine monophosphate. Sitagliptin (Compound II) is chemically named 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-trifluoromethyl-1,2,4-triazolo[4,3-a]pyrazine, which can prevent DPP-4 from hydrolyzing incretin hormones, thereby increasing the plasma concentration of active forms of GLP-1 and GIP, thereby improving blood glucose control in patients with type 2 diabetes. It has the advantages of good safety and low incidence of adverse reactions.
[0003] The use of transaminase biocatalysts is currently the main way to synthesize sitagliptin in industry, with advantages such as high substrate conversion rate, high stereoselectivity, and simple route. The key factor in this process - the improvement of the enzyme activity or other properties of the biocatalyst has always been a hot topic in the research and development of the pharmaceutical field.
[0004] Patent document with publication number CN102405281B discloses that based on (R)-ω-aminotransferase from Arthrobacter sp., the amino acid site combination mutation, protein three-dimensional structure computer-aided design, site-directed saturation mutation, whole gene sequence random mutation and other methods are used to obtain a transaminase mutant that can efficiently catalyze (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one (Compound I, CAS No. 764667-65-4) to synthesize sitagliptin in a 50% aqueous phase-50% DMSO organic phase.
[0005]
[0006] In recent years, we have also successively reported in patent documents with publication numbers CN112094856B, CN115873816A, CN116240189A and WO2024 / 098269A1 the research progress on the selective amination reaction of compound I (CAS No. 764667-65-4) catalyzed by transaminases or their mutants derived from Neosartorya fischeri and Arthrobacter sp. KNK168 to prepare sitagliptin.
[0007] The above enzymatic process has the advantages of high product yield and high production efficiency. However, if DMSO is used as an organic cosolvent in the reaction system, it is expensive and the post-processing is complicated, resulting in increased production costs. Methanol also has good solubility for substrates and products. Relatively speaking, methanol is cheap and easier to process after the reaction as a cosolvent. Therefore, using methanol as an alternative solvent can reduce the production cost of sitagliptin. However, the source of Arthrobacter sp. (R) -ω-transaminase is single, and the related mutant sequences and mutation sites are protected by many patents. Therefore, it is urgent to develop a new transaminase reaction system suitable for methanol dissolution. Summary of the invention
[0008] The new transaminase should ideally meet several requirements: first, it should have position selectivity when catalyzing the keto-transamination reaction of compound I, that is, only the 3-position keto group is selected among the two keto groups, but the 2-position keto group has no effect; second, it should have high stereoselectivity / spatial structural selectivity, that is, only the 3-position keto group is converted to the R-configuration amino group, but it will not racemize, and it will not be converted to the S-configuration only; third, the pocket-channel structure of the enzyme active center should maintain structural stability in the environment of high-concentration organic solvent alcohols such as methanol / DMSO aqueous solution; fourth, the enzyme specific activity should be high; and fifth, it should be substrate-free and product-inhibitory or have very low inhibition. In order to find such a transaminase, we cooperated with the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, based on the amino acid sequence and structural model of the (R)-ω-transaminase that has been reported in the prior art to be used to catalyze the synthesis of sitagliptin (II) from compound I, and screened a synthetic transaminase through computer simulation calculations and experimental verification. Its model can be found in Figure 1 , the amino acid sequence is SEQ ID NO: 1, named AT0. Then, based on AT0, we also tried to further mutate AT0 and screened out some mutants with significantly improved enzyme activity, including a mutant enzyme with an amino acid sequence of SEQ ID NO: 3, named AT16. Specifically, the present invention includes the following technical solutions:
[0009] The first aspect of the present invention provides a transaminase for catalyzing the reaction of compound I, CAS No. 764667-65-4, to prepare sitagliptin, CAS No. 764667-65-4, which is a polypeptide selected from the following:
[0010] (a) a polypeptide having an amino acid sequence of SEQ ID NO: 1, designated herein as ATO;
[0011] (b) a conservative variant polypeptide derived from (a) which is formed by substituting, deleting or adding one or more amino acid residues in the amino acid sequence SEQ ID NO:1 and has the function of the polypeptide of (a); or
[0012] (c) a polypeptide having more than 90% homology, preferably more than 92% homology, preferably more than 95% homology, preferably more than 97% homology, preferably more than 98% homology, more preferably more than 99% homology with the polypeptide sequence defined in (a), and having an increased enzyme activity in a methanol solution reaction system compared to SEQ ID NO: 1.
[0013] MDIGINSDPMATMDKVFAGYAARQKAMEAAGNPLSEGIAWVEGEMVPLHEARIPMLDEGFMRSDLTYDVPSVWDGRFFRLDDHLSRLEASCAKLRLKLPLPREEVKKILVEMVAKSGIRDAFVEIIVTRGLKGVRGSRPEEIVNRLYMLVQPYVWVMEPEVQP VGGDAVIARTVRRVPPGSIDPTVKNLQWGDFVRGLFEASDRGATYPFLTDGDANLTEGSGFNIVLVKDGVLYTPDRGVLQGVTRKSVIDVANAKGFEVRVEYVPVEAAYHADEIFMCTTAGGIMPIRSLDGKPVNDGKVGPITGYWGLINHPELITPVE(SEQ ID NO:1).
[0014] The above enzyme activity refers to the enzyme activity of catalyzing the selective amination reaction (transamination reaction of converting the 3-keto group to an R-type chiral amino group) of compound CAS No. 764667-65-4, i.e., (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one to prepare sitagliptin.
[0015] Preferably, the above transaminase is a polypeptide having an amino acid sequence of SEQ ID NO: 3, which is named AT16 herein.
[0016] MDIGINSDPMATMDKAFAGYAARQKAMEAAGNPRSEGIAWVEGEMVPLHEARIPMLDEGFMRSDLTYDVPSVWDGRFFRLDAHLSRLEASCAKLRLKLPLPRVEVKKILVEMVDKSGIRDAFVEIIVTRGLKGVRGSRPEEIVNRLYMLVQPYVWLMEPEVQP VGGDAVIARTVRRVPPGSIDPTVKNLQWGDFVRGLFEGSDRGATYPFLTDGDANLTEGSGFNIALVKDGVLYTPDRGVLQGMTRKSVIDVANAKGFEVRVEYVPVEADYHADEIFMCTTAGGIMPTRSLDGKPVNDGKVGPITGYWGLINHPELITPVE(SEQ ID NO:3).
[0017] Transaminase AT16 is a mutant of AT0 in which the valine at position 16 is mutated to alanine (V16A), the leucine at position 34 is mutated to arginine (L34R), the aspartic acid at position 82 is mutated to alanine (D82A), the glutamic acid at position 103 is mutated to valine (E103V), the alanine at position 114 is mutated to aspartic acid (A114D), the valine at position 156 is mutated to leucine (V156L), the alanine at position 201 is mutated to glycine (A201G), the valine at position 227 is mutated to alanine (V227A), the valine at position 245 is mutated to methionine (V245M), the alanine at position 271 is mutated to aspartic acid (A271D), and the isoleucine at position 289 is mutated to threonine (I289T).
[0018] The second aspect of the present invention provides a gene encoding the transaminase as described above.
[0019] In one embodiment, the nucleotide sequence of the gene encoding the transaminase whose amino acid sequence is shown in SEQ ID NO:1 is SEQ ID NO:2, or a nucleotide sequence having more than 90% homology, preferably more than 92% homology, preferably more than 95% homology, preferably more than 97% homology, preferably more than 98% homology, and more preferably more than 99% homology to SEQ ID NO:2.
[0020] The nucleotide sequence of the gene encoding the transaminase whose amino acid sequence is shown in SEQ ID NO:3 is SEQ ID NO:4, or a nucleotide sequence having more than 90% homology, preferably more than 92% homology, preferably more than 95% homology, preferably more than 97% homology, preferably more than 98% homology, and more preferably more than 99% homology to SEQ ID NO:4.
[0021] The third aspect of the present invention provides a DNA molecule comprising the transaminase encoding gene as described above, for example, the nucleotide sequence SEQ ID NO: 2 or SEQ ID NO: 4. The DNA molecule is, for example, a transaminase expression cassette.
[0022] Accordingly, the present invention also provides a recombinant plasmid comprising the DNA molecule described above. The plasmid is, for example, a vector suitable for expressing the above coding genes such as SEQ ID NO: 2 and SEQ ID NO: 4 in bacteria, preferably a vector of the PET series, such as pET22b, pET24a, pET28a, etc., but is not limited thereto.
[0023] The fourth aspect of the present invention provides a microbial engineering bacterium for expressing the above-mentioned transaminase, wherein the above-mentioned coding gene is integrated into its genome, or the microbial engineering bacterium is a transformant transformed with the above-mentioned recombinant plasmid.
[0024] Optionally, the integration of the above-mentioned coding gene can be implemented by gene editing technology. The above-mentioned gene editing technology is selected from the following group: homologous double exchange, TALEN system, CRISPR-Cas9 system, CRISPR-Cpf1 system, CRISPR-Cas12 system, CRISPR-BEST system, MuGENT (multiplex genome editing by natural transformation), etc.
[0025] The above recombinant plasmid can be transformed into a competent host cell by conventional chemical transformation or electroporation.
[0026] In one embodiment, preferably, the microorganism is a microorganism with a fast growth rate and suitable for expressing exogenous recombinant proteins, for example, selected from Bacillus subtilis, Lactobacillus brevis, Escherichia coli, Candida magnolii, Pichia pastoris, Saccharomyces cerevisiae. Preferably, the microorganism is Escherichia coli, more preferably Escherichia coli BL21 (DE3).
[0027] Another aspect of the present invention provides use of the above-mentioned transaminase or the above-mentioned microbial engineering bacteria in the production of sitagliptin.
[0028] As an embodiment of the above-mentioned use, in a reaction system containing methanol as a co-solvent, compound CAS No. 764667-65-4, i.e., (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one, is used as a reaction substrate, and the amino transfer reaction is catalyzed by the above-mentioned transaminase or the above-mentioned microbial engineering bacteria to obtain sitagliptin.
[0029] Preferably, the reaction system comprises triethanolamine, o-phenylenediamine dihydrochloride and / or isopropylamine as an amino group donor.
[0030] Furthermore, pyridoxal phosphate (PLP) can be added to the above reaction system as a coenzyme to promote the reaction.
[0031] Further, the reaction temperature can be 35-50° C., preferably 38-49° C., preferably 39-48° C., preferably 40-46° C., preferably about 45° C. The reaction pH can be 7.0-9.5, preferably pH 7.5-9.2, preferably pH 7.8-9.0, preferably pH 8.0-8.8, preferably pH 8.3-8.6, for example, about pH 8.5.
[0032] Furthermore, the methanol concentration in the reaction system is 40%-60%, preferably 50%. The concentration of substrate I is 20-200 g / L, preferably 50-100 g / L.
[0033] The present invention constructs an artificial transaminase AT0 for catalyzing the reaction of compound CAS No. 764667-65-4 to synthesize sitagliptin based on bioinformatics data, and the reaction is experimentally verified, which provides theoretical support for the artificial directional design of transaminase for specific purposes; the mutant AT16 has higher enzyme activity, and the stereoselectivity of AT0 and AT16 is very high, and the environment with high methanol concentration is tolerant, which is helpful to reduce the production cost of sitagliptin. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 This is the 3D model structure diagram of transaminase AT0.
[0035] Figure 2 It is a schematic diagram of the pET-AT0 plasmid expressing transaminase AT0.
[0036] Figure 3 It is the HPLC spectrum of the synthesis of compound II from substrate I catalyzed by transaminase AT16.
[0037] Figure 4It is the HPLC spectrum of the S-isomer produced when transaminase AT16 catalyzes the synthesis of compound II from substrate I. DETAILED DESCRIPTION
[0038] The transaminase AT0 designed by the present invention based on the amino acid sequence and structural model of the prior art transaminase is an artificially designed enzyme that overcomes the defect that many natural transaminases and their mutants are intolerant to high methanol concentration environments. The total length of the amino acid sequence of the artificial enzyme is 322 amino acid residues, of which the first 306 amino acids are derived from the transaminase sequence of Thermomyces stellatus, which is consistent with the first 306 amino acid sequence of PDB No. 6XWB_A; the 307th to 321st amino acids are derived from Nocardioides sp.CER19, which is consistent with the 313th to 327th amino acid sequence of NCBI No. WP_279881699.1; the 322nd amino acid is glutamic acid (E); the structural model is as follows Figure 1 shown.
[0039] It is expected that, based on the sequence and structure of ATO, those skilled in the art can further modify it to obtain mutants with one or more amino acid residues changed or deleted, so as to enhance, improve or change the performance in a certain aspect. Preferably, these mutations are conservative, that is, they do not change the catalytic activity of the enzyme that catalyzes the selective transamination reaction of compound I (CAS No. 764667-65-4) to generate compound II. For example, the enzyme activity of mutant AT16 is significantly improved compared with the starting transaminase ATO.
[0040] In this article, the terms "starting (type) enzyme", "initial (type) enzyme" and "starting enzyme" have the same meaning, and all refer to the transaminase AT0 with an amino acid sequence of SEQ ID NO: 1. Sometimes for the sake of convenience, the starting enzyme and its mutants such as AT16 can be collectively referred to as "transaminase" in this article.
[0041] As used herein, the term "(enzyme activity) increase" or "increase" as used above means an increase of at least 100% compared to a reference level, for example, an increase of at least about 1 times, at least about 2 times, or at least about 3 times, or at least about 5 times, or at least about 10 times, or at least about 20 times compared to a reference level.
[0042] The "mutation" includes but is not limited to replacement, deletion, insertion, chemical modification of amino acid residues, preferably a forward mutation, i.e. a mutation that improves enzyme activity. The substitution can be a non-conservative substitution, a conservative substitution, or a combination of a non-conservative substitution and a conservative substitution. "Conservative" amino acid substitution or mutation refers to the interchangeability of residues with similar side chains, and therefore generally includes replacing the amino acids in the polypeptide with the same or similar amino acid definition categories. However, as used herein, if a conservative mutation can be replaced by aliphatic to aliphatic, non-polar to non-polar, polar to polar, acidic to acidic, basic to basic, aromatic to aromatic, or restricted residue to restricted residue substitution, then a conservative mutation does not include a hydrophilic to hydrophilic, hydrophobic to hydrophobic, hydroxyl-containing to hydroxyl-containing or small residue to small residue substitution. It is well known in the art that common cases of conservative substitutions include: mutual substitutions between aromatic amino acids F, W, and Y; mutual substitutions between hydrophobic amino acids L, I, and V; mutual substitutions between polar amino acids Q and N; mutual substitutions between basic amino acids K, R, and H; mutual substitutions between acidic amino acids D and E; and mutual substitutions between hydroxyl amino acids S and T. In addition, A, V, L, or I can be conservatively mutated to another aliphatic residue or another non-polar residue. Exemplary conservative substitutions are, for example:
[0043]
[0044] "Non-conservative substitution" refers to the substitution or mutation of an amino acid in a polypeptide with an amino acid having significantly different side chain properties. Non-conservative substitutions may use amino acids between, rather than within, the defined groups listed above. In one embodiment, a non-conservative mutation affects (a) the structure of the peptide backbone in the area of the substitution (e.g., proline for glycine), (b) charge or hydrophobicity, or (c) side chain bulk.
[0045] "Deletion" refers to a modification of a polypeptide by removing one or more amino acids from a reference polypeptide. Deletion can include removal of 1 or more amino acids, 2 or more amino acids, 5 or more amino acids, 10 or more amino acids, 15 or more amino acids, or 20 or more amino acids, up to 10% of the total number of amino acids constituting the reference enzyme, while retaining enzymatic activity and / or retaining the improved properties of the engineered aminotransferase. Deletion can be directed to the interior and / or ends of a polypeptide. In various embodiments, deletion can comprise a continuous segment or can be discontinuous.
[0046] "Insertion" refers to the modification of a polypeptide by adding one or more amino acids from a reference polypeptide. In some embodiments, the improved engineered transaminases include the insertion of one or more amino acids into naturally occurring transaminases and the insertion of one or more amino acids into other improved transaminase polypeptides. The insertion can be internal to the polypeptide, or at the carboxyl or amino termini. Insertion as used herein includes fusion proteins as known in the art. Insertions can be continuous amino acid segments or separated by one or more amino acids in the naturally occurring polypeptide.
[0047] The aminotransferase AT0 and its mutant AT16 of the present invention have 322 amino acids and a clear structure, so it is easy for those skilled in the art to obtain its encoding genes, expression cassettes and plasmids containing these genes, and transformants containing the plasmids. These genes, expression cassettes, plasmids, and transformants can be obtained by genetic engineering construction methods well known to those skilled in the art.
[0048] In order to optimally express transaminase in the most commonly used Escherichia coli in genetic engineering, the expression genes of these enzymes can be codon optimized. Codon optimization is a technology that can be used to maximize protein expression in organisms by increasing the translation efficiency of the gene of interest. Different organisms usually show the special preference for one of some codons of the same amino acid being encoded due to mutation tendency and natural selection. For example, in fast-growing microorganisms such as Escherichia coli, the optimization codon reflects the composition of its respective genome tRNA library. Therefore, in fast-growing microorganisms, the low-frequency codons of amino acids can be replaced with codons for the same amino acids but with high frequency. Therefore, the expression of the optimized DNA sequence is improved in fast-growing microorganisms.
[0049] For example, to express a transaminase in E. coli, the gene encoding the codon-optimized starting transaminase SEQ ID NO: 1 can be SEQ ID NO: 2; and the gene encoding the transaminase mutant SEQ ID NO: 3 can be SEQ ID NO: 4.
[0050] The above-mentioned transformant host can be any microorganism suitable for expressing transaminase, including bacteria and fungi. Preferably, the microorganism is Bacillus subtilis, Corynebacterium glutamicum, Pichia pastoris, Saccharomyces cerevisiae, or Escherichia coli, preferably Escherichia coli, more preferably Escherichia coli BL21 (DE3).
[0051] When used as a biocatalyst for the production of sitagliptin, the transaminase of the present invention can be in the form of an enzyme or a bacterial cell. The enzyme forms include free enzymes, immobilized enzymes, including purified enzymes, crude enzymes, fermentation broths, enzymes fixed on carriers, etc.; the bacterial cells include living bacterial cells, dead bacterial cells, immobilized bacterial cells, etc.
[0052] When microorganisms such as Bacillus subtilis, Corynebacterium glutamicum, Pichia pastoris, Saccharomyces cerevisiae or Escherichia coli are no longer fermented and proliferated, but are directly used for enzyme catalysis, the bacteria itself is a natural immobilized enzyme, and does not need to be crushed or even extracted and purified, and can be used as an enzyme preparation for catalytic reactions. Since both the reaction substrate and the reaction product are small molecules, they can easily pass through the biological barrier of the bacteria - the cell membrane, so there is no need to crush the bacteria, which is economically advantageous.
[0053] The present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0054] Example
[0055] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned here refer to the mass percentages unless otherwise specified.
[0056] Materials and methods
[0057] The whole gene synthesis, primer synthesis and sequencing in the examples were all completed by Suzhou Genewise Biotechnology Co., Ltd.
[0058] The molecular biology experiments in the embodiments include plasmid construction, enzyme digestion, ligation, competent cell preparation, transformation, culture medium preparation, etc., and are mainly carried out with reference to Molecular Cloning Experiment Guide (3rd edition), edited by J. Sambrook and DW Russell (USA), translated by Huang Peitang et al., Science Press, Beijing, 2002). If necessary, the specific experimental conditions can be determined by simple experiments.
[0059] PCR amplification experiments were performed according to the reaction conditions provided by the plasmid or DNA template supplier or the kit instructions. If necessary, adjustments could be made through simple experiments.
[0060] LB medium: 10g / L tryptone, 5g / L yeast extract, 10g / L sodium chloride, pH 7.2. (LB solid medium plus 20g / L agar powder.)
[0061] TB medium: 24g / L yeast extract, 12g / L tryptone, 16.43g / L K2HPO4.3H2O, 2.31g / L KH2PO4, 5g / L glycerol, pH 7.0-7.5. (TB solid medium plus 20g / L agar powder.)
[0062] The fermentation medium of the 5L fermenter is: 24g / L yeast extract, 12g / L tryptone, 16.43g / LK2HPO4.3H2O, 2.31g / L KH2PO4, 5g / L glycerol, 0.5g / L defoaming agent, pH 7.0-7.5, and the fermentation liquid volume of each tank is 2L.
[0063] Feed medium for 5 L fermenter: 60% glycerol.
[0064] Kanamycin (Kan, 50 μg / mL) was used as required according to the antibiotic gene carried by the plasmid.
[0065] Protein purification reagents:
[0066] 1M PB solution: Take 174g of potassium dihydrogen phosphate and dilute it to 1L of ultrapure water (the pH value of potassium dihydrogen phosphate is adjusted to 7.1).
[0067] 4M sodium chloride solution: Take 117g of sodium chloride and dilute it to 0.5L of ultrapure water.
[0068] 4M imidazole solution: Take 136g imidazole and dilute it to 0.5L ultrapure water.
[0069] Balance solution: Dissolve 50 g glycerol, 13 mL sodium chloride mother solution, and 10 mL 1M PB solution in 100 mL water, then add ultrapure water to make up to 500 mL.
[0070] Impurity removal solution: Take 20g glycerol, 5mL 4M sodium chloride solution, 4mL 1M PB solution, and 1.25mL 4M imidazole solution and dissolve them in 100mL ultrapure water, then add ultrapure water to make up to 200mL (adjust the pH to 7.1 with hydrochloric acid).
[0071] Coomassie Brilliant Blue colorimetric solution: Weigh 100 mg of Coomassie Brilliant Blue G-250, dissolve in 50 mL of 90% ethanol, add 100 mL of 85% phosphoric acid, and add ultrapure water to make up to 1000 mL.
[0072] Eluent: Dissolve 20 g of glycerol, 5 mL of 4 M sodium chloride solution, 4 mL of 1 M PB solution, and 12.5 mL of 4 M imidazole solution in 100 mL of ultrapure water, then add ultrapure water to make up to 200 mL (adjust pH to 7.1 with hydrochloric acid).
[0073] Desalting equilibrium solution: Take 10mL of 1M PB solution and dilute to 500mL with ultrapure water.
[0074] HPLC detection conditions:
[0075] Chromatographic column C18 (4.6×250 mm, 5 μm);
[0076] Mobile phase A:mobile phase B=7:3 (mobile phase A: 10 mM K2HPO4, 0.1% triethylamine, pH 3.5; mobile phase B: acetonitrile);
[0077] Flow rate: 1.0 mL / min;
[0078] The detection wavelength is 210 nm.
[0079] Chromatographic conditions for chiral detection of sitagliptin: chromatographic column CHIRALPAK AD-H (4.6×250 mm, 5 μm); mobile phase n-hexane:ethanol:triethylamine (40:60:0.1); flow rate 0.7 mL / min, detection wavelength 268 nm.
[0080] It should be noted that, for the sake of convenience of description, in the embodiments, the strain number, plasmid number, enzyme number, and enzyme encoding gene number may share one number, which is easily understood by those skilled in the art, that is, the same number can refer to different biological forms in different environments.
[0081] Example 1: Transaminase structure design
[0082] The steps for obtaining and modeling artificial transaminase sequences are briefly described as follows:
[0083] All artificial transaminase sequences were designed using the SCHEMA software developed by Francis Arnold's team at California Institute of Technology. The design process is as follows: Use the https: / / www.ebi.ac.uk website to input the transaminase sequences in the company's transaminase library (including the public wild-type transaminase sequence, the artificial sequence 3 of Chinese patent application number CN202111141071.X, and the artificial sequence 3 of Chinese patent application number CN202111516721.4) as templates, use SCHEMA software to generate 6536 sequences, and select low <e>Value, High <m>The results of the values were combined to obtain the spliced sequence. The website https: / / clean.frontend.mmli1.ncsa.illinois.edu was used to verify that the obtained sequences were all transaminase sequences.
[0084]
[0085] SCHEMA recombination maximizes the probability that the chimeric protein library will function by using structural information to select crossover positions that minimize disruption of the folded structure. The number of residue pairs within . <e>: The average energy of the side chain contacts when the exchange block is disconnected; <m>: The average mutation level of each block; <e>and <m>There are checks and balances between them. Selection criteria: Low <e>,high <m>Lower <e>This means that there are more functional combinations in the library. For medium-sized proteins (250–500 amino acids), choose <e>SCHEMA libraries with less than 30 entries.
[0086] The recommended / candidate sequences obtained by SCHEMA software design include the amino acid sequence shown in SEQ ID NO: 1. Named ATO herein, whether ATO has transaminase activity is investigated through the following examples.
[0087] The structural model of transaminase ATO constructed based on the amino acid sequence SEQ ID NO: 1 is as follows Figure 1 The 3D structure of AT0 also shows 25 sites around the enzyme active pocket.
[0088] Example 2: Construction of initial enzyme AT01 expression strain
[0089] 2.1 Based on the amino acid sequence of AT0, SEQ ID NO:1, codon optimization was performed according to the codon preference of E. coli to obtain the nucleotide sequence of the coding gene, SEQ ID NO:2. The whole gene was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd. and cloned into the NdeI and XhoI sites of plasmid pET24a to obtain the recombinant plasmid pET-AT0. Figure 2 .
[0090] 2.2 The recombinant plasmid pET-AT0 was transformed into the expression host Escherichia coli BL21 (DE3) by electroporation to obtain the recombinant Escherichia coli expressing the initial aminotransferase, which was named EcAT0.
[0091] Example 3: Extraction of initial enzyme AT01 and investigation of enzyme activity
[0092] 3.1 Fermentation of strain EcAT0
[0093] Pick a single EcAT0 colony from the LB plate, transfer it to LB medium containing 50 μg / mL kanamycin, and culture it overnight at 37°C and 220 rpm; then transfer it to 100 mL TB medium containing 50 μg / mL kanamycin according to a 1% v / v inoculation amount, culture it at 37°C until OD600 reaches about 1.2, add a final concentration of 0.2 mM IPTG to induce protein expression, and induce it at 25°C for 20 hours to obtain recombinant bacteria expressing AT0. Collect the bacteria by centrifugation at 4°C and 12000 rpm for 10 minutes, and wash the bacteria once with 0.1 M potassium phosphate buffer (pH 8.0).
[0094] 3.2 Enzyme extraction and purification
[0095] The extraction and purification steps of the enzyme protein include: 1) resuspending the bacteria at a concentration of 15% v / v with a balance solution, performing ultrasonic disruption, centrifuging for 30 minutes, and collecting the supernatant after disruption. 2) Using 4 column volumes of balance solution to balance the His tag protein purification column, and passing the supernatant through the column. 3) Using 4 column volumes of impurity removal solution to pass through the column to remove impurities, and after the Coomassie brilliant blue of the impurity removal solution turns light blue, add the elution solution. 4) Eluting with 3 column volumes of elution solution until the Coomassie brilliant blue turns light blue. 5) Taking the eluted sample with the darkest Coomassie brilliant blue color and placing it on a desalting column, the desalting column is first balanced with a desalting balance solution, and then the eluted sample is placed on the column, and the absorbance of the eluted liquid is monitored by an ultraviolet spectrophotometer. After the absorbance is greater than 0.1, the desalted sample is collected, and the desalting is terminated after the absorbance drops back to 0.1. Thus, an enzyme solution is prepared.
[0096] 3.3 Enzyme activity identification
[0097] The 30 mL reaction system includes 0.1 mL enzyme solution, 20 g / L compound I, 0.5 g / L pyridoxal phosphate, 1 M isopropylamine, 100 mM, 50% methanol, and the pH value is adjusted to 8.5 with hydrochloric acid. After the sample is filtered and analyzed by HPLC, it is found that ATO has transaminase activity that catalyzes the synthesis of compound II from compound I, and the specific activity is measured to be 0.38 U / mg, and the product II is almost entirely 3R-configuration, and the calculated ee value is greater than 99.95%.
[0098] Herein, 1 unit (U) is defined as the amount of enzyme capable of producing 1 μmole of Compound II per minute.
[0099] This example confirms that the artificial transaminase of the present invention was successfully constructed, and verifies that the SCHEMA software can be used for the design of certain types of enzymes with shorter amino acid sequences.
[0100] Then, based on AT0, attempts were made to improve enzyme activity by artificial mutation through traditional error-prone PCR method in order to obtain mutants with higher enzyme activity.
[0101] Example 4: Construction of random mutation point library from round 1 to round 2 and high-throughput reaction screening
[0102] 4.1 Construction of random mutation point library by error-prone PCR
[0103] The random mutant library was constructed using error-prone PCR technology with plasmid pET-AT0 as template.
[0104] Design the following primer pair AT-5 / AT-3:
[0105] Forward primer AT-5: 5'-ATGGATATCGGTATTAACAG-3',
[0106] Reverse primer AT-3: 5′-TTCAACCGGGGTAATCAGTT-3′.
[0107] Using plasmid pET-AT0 as a template, PCR amplification was performed to obtain a transaminase mutant DNA sequence of approximately 1.0 kb.
[0108] The 50 μL error-prone PCR reaction system included: 10 ng plasmid (pET-AT0) template, 50 pmol of a pair of primers AT-5 and AT-3, 1× Taq buffer, 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP, 1 mM dTTP, 7 mM MgCl2, (0 mM, 0.05 mM, 0.1 mM, 0.15 mM, 0.2 mM) MnCl2, and 2.5 units of Taq enzyme (Takara).
[0109] The PCR reaction conditions were: 95°C for 5 min; 94°C for 30 s, 55°C for 30 s, 72°C for 2 min / kbp, 30 cycles; 72°C for 10 min.
[0110] The PCR product was electrophoresed and recovered by gel (Axygen DNA gel recovery kit AP-GX-50). Using plasmid pET-AT0 as template and the recovered product of about 1.0 kb (random mutation fragment) as large primer, MegaPrimer PCR was performed with KOD-plus DNA polymerase: 94℃5min; 98℃10s, 60℃30s, 68℃2min / kb, 25 cycles; 68℃10min. The plasmid template was digested with DpnI restriction endonuclease (Thermo Company) and electroporated into E. coli BL21 (DE3), and more than 10 4 A random mutation library of 10 clones.
[0111] 4.2 High-throughput screening of mutant libraries
[0112] Pick a single mutant colony to a 96-well plate (each well contains 110 μL of liquid LB-Kan medium), incubate at 37°C and 400 rpm for 5 hours, then take out 60 μL of bacterial solution from each well to a 96-well deep-well plate (each well contains 240 μL of liquid TB-Kan-0.2 mM IPTG), and incubate at 25°C and 400 rpm for 12 to 16 hours. Centrifuge at 4°C and 4000 rpm for 10 minutes to collect the cells, and remove the supernatant culture medium. Subsequently, wash the cells with pre-cooled saline, centrifuge at 4°C and 4000 rpm for 10 minutes to collect the cells, and remove the supernatant. Add 200 μL of enzyme reaction solution (100 mM triethanolamine, 70 mM o-phenylenediamine dihydrochloride, 0.5 g / L pyridoxal phosphate, 10 g / L compound I, 50% methanol) to each well, adjust the pH to 8.5 for reaction. Resuspend the cells, incubate at 45°C, 250 rpm for 1 to 5 h, and detect the value at 475 nm. The larger the value, the higher the enzyme activity.
[0113] 4.3 Gene sequencing of mutant strains
[0114] The enzyme activity of the strains with significantly improved enzyme activity was reviewed, and the ee values of the reaction products of these strains were detected by HPLC. The strains with product ee values greater than 99.95% and the highest improvement in enzyme activity were selected as the starting strains for the next round of random mutant library construction. Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to sequence the genome of the strains with the highest enzyme activity, and the amino acid sequence changes of the mutant enzymes were determined by comparing the corresponding genes. Repeat the establishment of the random mutation library and the high-throughput screening of the reaction system with compound I as the substrate and methanol as the solubilizer. The screening results are shown in Table 1.
[0115] Table 1. Results of high-throughput screening of the first and second rounds of random mutation libraries
[0116]
[0117] Note: "+" represents that the percentage of enzyme activity is greater than 0% and less than or equal to 50% relative to the respective starting strain; "++" represents that the percentage of enzyme activity is greater than 50% and less than or equal to 100% relative to the respective starting strain; "+++" represents that the percentage of enzyme activity is greater than 100% and less than or equal to 200% relative to the respective starting strain; "++++" represents that the percentage of enzyme activity is greater than 200% relative to the respective starting strain.
[0118] The mutant strain EcAT9 obtained by two rounds of error-prone PCR not only significantly improved the enzyme activity but also maintained a high degree of stereoselectivity.
[0119] Example 5: Construction of random mutation point library from round 3 to round 4 and high-throughput reaction screening
[0120] 5.1 Construction of random mutation point library by error-prone PCR
[0121] The mutant AT9 screened in Example 4 was subjected to plasmid extraction using a plasmid extraction kit, and the plasmid was used as a template to construct a random mutation library. The construction method was based on method 4.1 for constructing a random mutation point library of transaminase in Example 4.
[0122] 5.2 High-throughput screening of mutant libraries
[0123] Referring to the method in step 4.2 above, pick a single mutant colony to a 96-well plate (each well contains 110 μL of liquid LB-Kan medium), incubate at 37°C and 400 rpm for 5 hours, then take out 60 μL of bacterial solution from each well to a 96-well deep-well plate (each well contains 240 μL of liquid TB-Kan-0.2 mM IPTG), and incubate at 25°C and 400 rpm for 12 to 16 hours. Centrifuge at 4°C and 4000 rpm for 10 minutes to collect the bacteria, and remove the supernatant culture medium. Subsequently, wash the bacteria with pre-cooled saline, centrifuge at 4°C and 4000 rpm for 10 minutes to collect the bacteria, and remove the supernatant. Add 100 uL of 50% water-50% methanol solution to each well to resuspend the cells, and incubate at 45°C and 800 rpm for 30 minutes. Then, add enzyme reaction solution to each well to make up to 200 μL, which finally contains 70 mM triethanolamine, 70 mM o-phenylenediamine dihydrochloride, 0.5 g / L pyridoxal phosphate, 20 g / L compound I, and 50% methanol, and adjust the pH value to 8.5 for reaction. Resuspend the cells, incubate at 45°C and 250 rpm for 1 to 5 hours, and detect the value at 475 nm. The larger the value, the higher the enzyme activity.
[0124] 5.3 Gene sequencing of mutant strains
[0125] Referring to the method in step 4.3 above, the enzyme activity of the strains with significantly improved enzyme activity was reviewed, and the ee values of the reaction products of these strains were detected by HPLC at the same time. The strains with product ee values greater than 99.95% and the highest improvement in enzyme activity were selected as the starting strains for the next round of random mutant library construction. Suzhou Jinweizhi Biotechnology Co., Ltd. was commissioned to sequence the genome of the strains with the highest enzyme activity, and the amino acid sequence changes of the mutant enzymes were determined by comparing the corresponding genes. Repeat the establishment of the random mutation library and the high-throughput screening of the reaction system with compound I as the substrate and methanol solubilization. See Table 2 for the screening results.
[0126] Table 2. Results of high-throughput screening of the third and fourth rounds of random mutation libraries
[0127]
[0128]
[0129] Note: "+" represents that the percentage of activity is greater than 0% and less than or equal to 50% relative to the respective starting strain; "++" represents that the percentage of activity is greater than 50% and less than or equal to 100% relative to the respective starting strain; "+++" represents that the percentage of activity is greater than 100% and less than or equal to 200% relative to the respective starting strain; "++++" represents that the percentage of activity is greater than 200% relative to the respective starting strain.
[0130] After four rounds of error-prone PCR, the mutant strain EcAT16 obtained not only has a significantly improved enzyme activity compared to the starting strain EcAT0, but also still maintains a high degree of stereoselectivity. The nucleotide sequence of the coding gene of the aminotransferase AT16 expressed by it is sequenced as SEQ ID NO:4, and the corresponding amino acid sequence is SEQ ID NO:3, which is the V16A, L34R, D82A, E103V, A114D, V156L, A201G, V227A, V245M, A271D, I289T mutant of AT0.
[0131] Example 6: Investigation of strain fermentation and direct catalytic reaction of bacteria
[0132] 6.1 The strains EcAT0 and EcAT16 were cultured in fermenters as follows: single colonies were picked from LB plates and placed in 5 mL of liquid LB medium containing Kan, and cultured overnight at 37°C and 220 rpm. The next day, the inoculation volume was transferred to a shake flask containing 100 mL of liquid TB medium at a volume concentration of 5% v / v, and cultured at 37°C and 220 rpm until OD 600nm After reaching 6, it was transferred to a 5L fermentation tank as seed liquid. After inoculation, it was cultured at 400-800 rpm / min and 37°C, and the dissolved oxygen was controlled within the range of 20-30%. 600nm After reaching 20, IPTG was added to induce transaminase expression, the final concentration of IPTG was 0.2 mM, and the culture was continued at 28-30°C for 16-24 hours. The bacteria were collected by centrifugation and used to catalyze compound I to synthesize sitagliptin (II) in a 1L reaction system. Ammonia water was used to control the pH value of the whole fermentation process to 6.8-7.2, and the ventilation volume was controlled in the range of 2.5-3.5.
[0133] 6.2 In a 1L reaction system, EcAT0 and EcAT16 whole cells were used to catalyze the reaction of compound I to prepare sitagliptin (compound II). The reaction system includes: 100mM triethanolamine, 1M isopropylamine, 0.5g / L pyridoxal phosphate, 50g / L compound I, 50g / L cells (wet weight), and 50% methanol. First, compound I was dissolved in methanol and added to the reaction system at a flow rate of 1mL / min. The pH value of the reaction system was controlled at about pH 8.5 using hydrochloric acid or isopropylamine.
[0134] HPLC test results showed that the catalytic activity of EcAT16 was higher than that of EcAT0. After 20 h of reaction, the molar yield of the catalytic product II of EcAT16 exceeded 97% ( Figure 3 ), and the ee value of product II is greater than 99.95% (as shown Figure 4 This experiment proves that the artificial enzyme AT0 and its mutant AT16 have ideal transaminase activity in methanol, have further development potential, and have good industrial application prospects.< / e> < / e> < / m> < / e> < / m> < / e> < / m> < / e> < / m> < / e>
Claims
1. A transaminase for catalyzing the reaction of compound CAS No. 764667-65-4 to prepare sitagliptin, which is a polypeptide selected from the following: (a) a polypeptide having an amino acid sequence of SEQ ID NO: 1; (b) a conservative variant polypeptide derived from (a) which is formed by substituting, deleting or adding one or more amino acid residues in the amino acid sequence SEQ ID NO:1 and has the function of the polypeptide of (a); or (c) A polypeptide having more than 90% homology with the polypeptide sequence defined in (a) and having an enzyme activity in a methanol solution reaction system that is higher than that of SEQ ID NO:
1.
2. The transaminase according to claim 1, characterized in that The transaminase is a polypeptide having an amino acid sequence of SEQ ID NO:
3.
3. A gene encoding the transaminase according to claim 1 or 2.
4. The gene according to claim 3, characterized in that The nucleotide sequence of the gene encoding the transaminase whose amino acid sequence is shown in SEQ ID NO: 1 is SEQ ID NO: 2, or a nucleotide sequence having more than 90% homology with SEQ ID NO: 2; The nucleotide sequence of the gene encoding the transaminase with the amino acid sequence shown in SEQ ID NO:3 is SEQ ID NO:4, or a nucleotide sequence having more than 90% homology with SEQ ID NO:
4.
5. A DNA molecule, characterized in that A gene encoding the transaminase according to claim 4, such as the nucleotide sequence SEQ ID NO: 2 or SEQ ID NO:
4.
6. A recombinant plasmid, characterized in that: Comprising the DNA molecule as described in claim 5.
7. A microbial engineering bacterium for expressing the transaminase according to claim 1, characterized in that: The gene as claimed in claim 4 is integrated into the genome, or the transformant is transformed with the recombinant plasmid as claimed in claim 6.
8. The microbial engineering bacteria according to claim 7, characterized in that: The microorganism is Escherichia coli.
9. Use of the transaminase according to claim 1 or the microbial engineering bacteria according to claim 7 in the production of sitagliptin.
10. The use according to claim 9, characterized in that In a reaction system containing methanol as a cosolvent, the compound CAS No. 764667-65-4, i.e., (2Z)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7-(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one, is used as a reaction substrate, and the aminotransferase as claimed in claim 1 or the microbial engineering bacteria as claimed in claim 7 is used to catalyze the amino transfer reaction to obtain sitagliptin.
